Lightlake Therapeutics Takes Safer Approach to Obesity
01 Februar 2011 - 7:22PM
Marketwired
Lightlake Therapeautics ("Lightlake") (OTCBB: LLTP) After the
recent FDA decision concerning Orexigen's obesity medicine,
Contrave™ (naltrexone plus bupropion) Lightlake would like to
clarify that they do not anticipate the same cardiovascular
problems with their treatment of binge eating disorder with
naloxone alone.
Lightlake has found that opioid antagonists, such as naltrexone
and naloxone, when used properly, are highly effective when used as
single agents, for addictive behaviors such as binge eating. Opioid
antagonists are particularly safe and the opioidergic system can be
blocked with minimal side-effects.
"Lightlake's antagonist, naloxone, is "the safest antagonist
available" (1). In contrast to naltrexone that is given in a large
daily dose sufficient to block the opioid system 24 hours a day,
Lightlake uses a more precise method, administering a small dose of
naloxone that is present in significant quantities for only about 2
hours, i.e., the typical duration of an eating binge, and only on
the days when the patient is having an eating binge, leaving the
body free of medication the rest of the time. Furthermore we only
expect patients to be regularly using this medication on a daily
basis for the first two weeks and on an ad hoc basis afterwards.
Therefore patients will not be chronically exposed to our
treatment. Naturally, we are monitoring cardiovascular measures in
our Phase II clinical trial, but we do not anticipate any adverse
effects." stated Dr. David Sinclair, Chief Scientific Officer.
(1) Sneader, Walter (2005) Drug Discovery: A History.
Chichester, UK, Wiley, 468 p (quotation, p120.)
About Lightlake Therapeutics
Lightlake Therapeutics is an early stage biopharmaceutical
company aiming to build a solid platform of pharmacological
treatments based on our expertise using opioid antagonists.
Significant developments include the use of an opioid antagonist
nasal spray to address binge-eating obesity. A Phase II trial of
this product in Helsinki is due to be completed during 2011.
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contacts: Lightlake Therapeautics Dr Roger Crystal CEO
roger.crystal@lightlake.fi Lightlake Therapeautics Dr Michael
Sinclair Chairman michael.sinclair@lightlake.fi Press Inquiries:
TypeA Consulting, Inc. Christine Barisheff
Christine@typeaconsult.com
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024